On October 1st, the Paris judicial court convicted a pharmacologist and oncologist, along with two accomplices, for illegally administering an unapproved treatment to more than 400 patients with neurodegenerative disorders. The treatment, referred to as a miracle remedy, was not authorized by health authorities and was allegedly promoted as a cure for conditions such as Alzheimer’s disease and Parkinson’s disease. Neurodegenerative disorders are a group of conditions that involve the progressive loss of structure or function of neurons, leading to cognitive or physical decline. The accused individuals were found guilty of violating medical regulations by offering this unproven therapy without proper authorization. Their actions raised concerns about the safety and efficacy of the treatment, as well as the potential harm it could cause to vulnerable patients seeking relief from chronic and often incurable conditions. The court emphasized the importance of adhering to strict medical guidelines to protect public health. The case has sparked discussions about the regulation of experimental treatments and the need for transparency in medical practices. Health experts have warned that unapproved treatments can lead to serious consequences, including financial exploitation and physical harm to patients. The conviction serves as a reminder of the legal and ethical responsibilities of healthcare professionals. The pharmacologist and oncologist, who were central figures in the case, face significant legal repercussions, including potential fines and restrictions on their medical licenses. Their accomplices also received convictions, though the specific penalties were not disclosed in the initial court ruling. This case highlights the ongoing challenges in balancing medical innovation with patient safety and regulatory oversight.